A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
← catalyst calendarNCT07316062 · readout in 985 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,000estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-29 | actual | When the study began enrolling |
| Primary completion | 2029-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small-Cell Lung
Primary outcomes
what the primary-completion date above is the date OFTreatment Patterns
measured Up to 50 months
Proportion of unresected patients in SI/II/III
measured Up to 50 months
CRT rate in USIII
measured Up to 50 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed